



## Zafgen to Present at the Leerink Partners 7th Annual Global Healthcare Conference

February 8, 2018

BOSTON, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield, Chief Executive Officer of Zafgen, Inc. will participate in a fireside chat discussion at the Leerink Partners 7<sup>th</sup> Annual Global Healthcare Conference on Thursday, February 15, 2018 at 3:00 p.m. ET.

A live audio webcast and replay of the presentation will be available through the Events and Presentations page of the Investors section of the Company's website ([www.zafgen.com](http://www.zafgen.com)) for 90 days following the conclusion of the live event.

### About Zafgen

Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders, and its current disease areas of focus are type 2 diabetes, Prader-Willi syndrome and liver diseases. The company's lead product candidate is ZGN-1061, a MetAP2 inhibitor in Phase 2 clinical development with unique properties that maximize impact on metabolic parameters relevant to the treatment of type 2 diabetes and other related metabolic disorders. In 2018, Zafgen plans to file an investigational new drug (IND) application with the U.S. FDA and initiate Phase 1 clinical trials for ZGN-1258, its new molecule for the treatment of Prader-Willi syndrome and potential other rare and serious forms of obesity. Learn more at [www.zafgen.com](http://www.zafgen.com).

### Media/Investor Relations Contact:

Zafgen, Inc.  
Patricia Allen  
Chief Financial Officer  
617-648-9792

Media  
Krystle Gibbs  
Ten Bridge Communications  
[krystle@tenbridgecommunications.com](mailto:krystle@tenbridgecommunications.com)  
508-479-6358

Investors  
Laura Perry or Mary Jenkins  
Argot Partners  
[laura@argotpartners.com](mailto:laura@argotpartners.com)  
[mary@argotpartners.com](mailto:mary@argotpartners.com)  
212-600-1902

[Primary Logo](#)

Source: Zafgen, Inc.